Sean J. Pittock, M.D.

The purpose of this study is to longitudinally measure cognitive performance in patients with multiple sclerosis and progressive immune-mediated neurodegenerative disorders in order to determine the rate of progression, and to establish quantitative functional biomarkers that can be used to measure treatment effectiveness in therapy trials directly targeting progressive immune-mediated neurodegeneration.

The purpose of this study is to find and identify autoreactive lymphocytes including autoantibody producing B cells and autoreactive T-cells.

The purpose of the study is to learn more about autoimmunity and potential mother to baby transmission of pathogenic antibodies. The collected research samples from children will be frozen and stored at the Mayo Clinic and will be used for future studies of autoimmune diseases.

The primary purpose of this study is to evaluate the effectiveness and safety of Ravulizumab for the treatment of adult participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).

The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.

The purpose of this study is to determine whether intravenous immunoglobulin (IVIG) treatment reduces significantly the number of epileptic seizures in cases of autoimmune epileptic seizures.

The primary objective of the study is to assess the efficacy and safety of eculizumab treatment as compared to placebo in relapsing NMO patients using a time to first relapse study design.

The purpose of this study is to establish a repository consisting of clinical information, radiological data, serum, peripheral blood lymphocytes, plasma, cerebrospinal fluid (CSF), DNA and tissue specimens collected prospectively from participants with cancer and autoimmune diseases.

The purpose of this study is to extend enrollment and follow up of participants in a registry for inflammatory diseases of the central nervous system.

The purpose of this study is to evaluate Mayo patients who have been seropositive for paraneoplastic antibodies with regards to their treatments and symptom progress.

The aim is to establish a repository consisting of clinical information, radiological data, serum, peripheral blood lymphocytes, plasma, cerebrospinal fluid (CSF), and tissue specimens collected prospectively from patients with CNS diseases and controls.

The purpose of this study is to collect information on the natural history of neuromyelitis optica spectrum disorder (NMOSD) in pediatric AQP4-IgG seropositive patients in the Mayo Clinic neuromyelitis optica spectrum disorder (NMOSD) Pediatric Repository.

The purpose of this study is to establish a repository consisting of clinical information, radiological data, serum, peripheral blood lymphocytes, plasma, cerebrospinal fluid (CSF), urine, stool, DNA and tissue specimens collected from patients who have central nervous system (CNS)  inflammatory diseases.